BASEL, Switzerland, Nov. 28 /CNW/ - With the public interest in Tamiflu continuing, Roche keeps interested physicians and governments updated on current developments and today, informs on the topic of resistance. There have been no new cases of resistance seen in patients infected with H5N1 virus (‘bird flu’) since March 2005 and scientific data does not substantiate increased resistance to Tamiflu (oseltamivir). Roche is providing this update on the topic so that physicians and governments can be confident that Tamiflu can continue to be effectively used in the treatment and prophylaxis of seasonal and H5N1 influenza.
